Mohit Bansal
Stock Analyst at Wells Fargo
(4.30)
# 436
Out of 4,732 analysts
149
Total ratings
59.77%
Success rate
12.97%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $62 → $57 | $54.80 | +4.01% | 6 | Jan 13, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $555 → $460 | $422.00 | +9.00% | 9 | Jan 10, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,050 → $900 | $681.58 | +32.05% | 16 | Jan 10, 2025 | |
| BIIB Biogen | Maintains: Equal-Weight | $190 → $165 | $140.55 | +17.40% | 12 | Jan 10, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $335 → $280 | $272.11 | +2.90% | 9 | Jan 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Overweight | $30 | $19.03 | +57.65% | 1 | Dec 11, 2024 | |
| BNTX BioNTech SE | Initiates: Overweight | $170 | $111.93 | +51.88% | 1 | Dec 11, 2024 | |
| VERA Vera Therapeutics | Initiates: Overweight | $70 | $33.37 | +109.77% | 1 | Nov 21, 2024 | |
| GILD Gilead Sciences | Maintains: Overweight | $100 → $105 | $91.84 | +14.33% | 9 | Nov 7, 2024 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $125 → $110 | $97.92 | +12.34% | 10 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $27 | $18.37 | +46.98% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $90 | $61.53 | +46.27% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $3.66 | +227.87% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $875 → $1,000 | $725.72 | +37.79% | 15 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $120 | $121.18 | -0.97% | 1 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $26.30 | +14.07% | 9 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $205 | $171.56 | +19.49% | 6 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $143.26 | +18.67% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $51 → $52 | $56.29 | -7.62% | 7 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $9.24 | +192.21% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $38.52 | +29.80% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $15.60 | +11,919.23% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $30 | $12.74 | +135.48% | 4 | Jan 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $1.11 | +3,143.24% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $22.11 | -14.07% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.58 | +762.22% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $2.53 | +2,271.54% | 4 | Dec 3, 2019 |
Halozyme Therapeutics
Jan 13, 2025
Maintains: Equal-Weight
Price Target: $62 → $57
Current: $54.80
Upside: +4.01%
Vertex Pharmaceuticals
Jan 10, 2025
Maintains: Overweight
Price Target: $555 → $460
Current: $422.00
Upside: +9.00%
Regeneron Pharmaceuticals
Jan 10, 2025
Maintains: Overweight
Price Target: $1,050 → $900
Current: $681.58
Upside: +32.05%
Biogen
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $190 → $165
Current: $140.55
Upside: +17.40%
Amgen
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $335 → $280
Current: $272.11
Upside: +2.90%
Summit Therapeutics
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $19.03
Upside: +57.65%
BioNTech SE
Dec 11, 2024
Initiates: Overweight
Price Target: $170
Current: $111.93
Upside: +51.88%
Vera Therapeutics
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $33.37
Upside: +109.77%
Gilead Sciences
Nov 7, 2024
Maintains: Overweight
Price Target: $100 → $105
Current: $91.84
Upside: +14.33%
Merck & Co.
Nov 1, 2024
Maintains: Equal-Weight
Price Target: $125 → $110
Current: $97.92
Upside: +12.34%
Oct 21, 2024
Upgrades: Overweight
Price Target: $9 → $27
Current: $18.37
Upside: +46.98%
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $61.53
Upside: +46.27%
Aug 9, 2024
Maintains: Overweight
Price Target: $14 → $12
Current: $3.66
Upside: +227.87%
Aug 9, 2024
Maintains: Overweight
Price Target: $875 → $1,000
Current: $725.72
Upside: +37.79%
Aug 1, 2024
Maintains: Equal-Weight
Price Target: $140 → $120
Current: $121.18
Upside: -0.97%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $26.30
Upside: +14.07%
Jul 26, 2024
Maintains: Overweight
Price Target: $200 → $205
Current: $171.56
Upside: +19.49%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $143.26
Upside: +18.67%
Apr 18, 2024
Maintains: Equal-Weight
Price Target: $51 → $52
Current: $56.29
Upside: -7.62%
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $9.24
Upside: +192.21%
Nov 28, 2022
Initiates: Overweight
Price Target: $50
Current: $38.52
Upside: +29.80%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $15.60
Upside: +11,919.23%
Jan 7, 2021
Maintains: Buy
Price Target: $25 → $30
Current: $12.74
Upside: +135.48%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $1.11
Upside: +3,143.24%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $22.11
Upside: -14.07%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.58
Upside: +762.22%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $2.53
Upside: +2,271.54%